

M. Sherry Ku, Ph.D., R.Pharm.

- ❑ Chairperson of Board/CEO, Savior Lifetech Corporation, a carbapenem company with double A strategy from API to ANDA (finished injectable vials). Savoir markets imipenem/cilastatin, and meropenem worldwide with >100 marketing partners, and >200 regulatory registrations over 80 countries. Ertapenem is being registered worldwide.
- ❑ Founding President and Board Member of RuenHuei Biopharmaceutical Company, a new drug development company with 3 new clinical lead compounds in the area of oncology and infectious diseases.
- ❑ Founding President/CSO of TWi Biotech/TWi Pharma (Anchen) with 6 High Barrier US ANDA filings within 18 months. Simultaneously established a pipeline of 6 new drugs including 3 biologicals.
- ❑ Head of Early pharmaceutical Development in Wyeth Research USA (now Pfizer). Her responsibilities starts from discovery interface through clinical proof of concept.
- ❑ Oversees new drug development for over 170 new clinical leads resulting in 85 original NME IND filings.
- ❑ Developed seven (7) commercial products including Suprax, Zosyn/Tazocin, Zebeta, Isovorin, Thioplex, Sonata and Tygacil from preformulation through NDA and FDA PAI activities.
- ❑ Sherry is a graduate of National Taiwan University (B.S.) and The Ohio State University (Ph.D.) in Pharmaceutics and Pharmaceutical Chemistry.
- ❑ She currently holds over 70 patents/invention disclosures and has additional 62 Journal publications.
- ❑ She was the Vice Chair of NJ Pharmaceutical Discussion Group and is the chair elect of AAPS Physical Pharmacy and Biopharmaceutical section
- ❑ She sits on USP expert council and consults for sFDA, tFDA, IPEC and various Quality Councils. She is a licensed Pharmacist.